About Onconova Therapeutics (NASDAQ:ONTX)
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biopharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:ONTX
- CUSIP: N/A
- Web: www.onconova.com
Capitalization:- Market Cap: $24.14 million
- Outstanding Shares: 9,851,000
Average Prices:- 50 Day Moving Avg: $1.92
- 200 Day Moving Avg: $2.04
- 52 Week Range: $1.46 - $3.88
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.32
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $2.36 million
- Price / Sales: 10.23
- Book Value: ($0.04) per share
- Price / Book: -61.25
Profitability:- EBITDA: ($22,150,000.00)
- Net Margins: -762.13%
- Return on Equity: -558.97%
- Return on Assets: -85.62%
Debt:- Current Ratio: 1.62%
- Quick Ratio: 1.62%
Misc:- Average Volume: 149,386 shs.
- Beta: 0.11
- Short Ratio: 15.94
Frequently Asked Questions for Onconova Therapeutics (NASDAQ:ONTX)
What is Onconova Therapeutics' stock symbol?
Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."
When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?
Shares of Onconova Therapeutics reverse split on Tuesday, May 31st 2016. The 1-10 reverse split was announced on Friday, May 20th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 30th 2016. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 10 shares after the split.
How were Onconova Therapeutics' earnings last quarter?
Onconova Therapeutics, Inc. (NASDAQ:ONTX) issued its quarterly earnings results on Monday, August, 14th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.43. The firm had revenue of $0.32 million for the quarter, compared to the consensus estimate of $0.25 million. Onconova Therapeutics had a negative net margin of 762.13% and a negative return on equity of 558.97%. View Onconova Therapeutics' Earnings History.
When will Onconova Therapeutics make its next earnings announcement?
Where is Onconova Therapeutics' stock going? Where will Onconova Therapeutics' stock price be in 2017?
4 brokers have issued 1 year price objectives for Onconova Therapeutics' shares. Their forecasts range from $6.00 to $10.00. On average, they expect Onconova Therapeutics' share price to reach $7.33 in the next year. View Analyst Ratings for Onconova Therapeutics.
Who are some of Onconova Therapeutics' key competitors?
Some companies that are related to Onconova Therapeutics include Cesca Therapeutics (KOOL), Tokai Pharmaceuticals (NVUS), Ocera Therapeutics (OCRX), Catalyst Biosciences (CBIO), Sonoma Pharmaceuticals (SNOA), Argos Therapeutics (ARGS), Auxilium Pharmaceuticals (AUXL), Baxalta (BXLT), Horizon Therapeutics (HPTX), Ocera Therapeutics (TZYM), Transition Therapeutics (TTHI) and Vitae Pharmaceuticals (VTAE).
Who are Onconova Therapeutics' key executives?
Onconova Therapeutics' management team includes the folowing people:
- Michael M. B Hoffman, Chairman of the Board
- Ramesh Kumar Ph.D., President, Chief Executive Officer, Director
- Mark Guerin, Chief Financial Officer
- Steven M. Fruchtman M.D., Senior Vice President - Research and Development, Chief Medical Officer
- Manoj Maniar Ph.D., Senior Vice President - Product Development
- Henry S. Bienen Ph.D., Director
- Jerome E. Groopman M.D., Director
- Viren Mehta Ph.D., Director
- E. Premkumar Reddy Ph.D., Director
- Jack E. Stover CPA, Director
How do I buy Onconova Therapeutics stock?
Shares of Onconova Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Onconova Therapeutics' stock price today?
One share of Onconova Therapeutics stock can currently be purchased for approximately $2.45.
MarketBeat Community Rating for Onconova Therapeutics (NASDAQ ONTX)MarketBeat's community ratings are surveys of what our community members think about Onconova Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Onconova Therapeutics (NASDAQ:ONTX)Earnings History by Quarter for Onconova Therapeutics (NASDAQ ONTX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/13/2017 | | ($0.73) | | | | | N/A |  |
| 8/14/2017 | Q2 2017 | ($0.72) | ($0.29) | $0.25 million | $0.32 million | View | N/A | |
| 5/15/2017 | Q1 2017 | ($0.96) | ($1.23) | | $0.21 million | View | N/A | |
| 11/14/2016 | Q3 2016 | ($0.82) | ($0.29) | $1.60 million | $1.70 million | View | N/A | |
| 8/15/2016 | Q2 | | ($1.96) | | $2.25 million | View | N/A | |
| 5/11/2016 | Q1 | ($0.19) | ($0.27) | $1.34 million | $1.47 million | View | N/A | |
| 3/28/2016 | Q4 | ($0.27) | $0.18 | | $9.60 million | View | N/A | |
| 11/11/2015 | Q3 | ($0.32) | ($0.26) | $0.11 million | $1.62 million | View | N/A | |
| 8/13/2015 | Q2 | ($0.56) | ($0.41) | $0.11 million | $0.12 million | View | N/A | |
| 5/14/2015 | Q1 | ($0.63) | ($0.57) | $0.11 million | $0.11 million | View | N/A | |
| 3/26/2015 | | ($0.71) | ($0.62) | | $0.11 million | View | N/A | |
| 11/13/2014 | | ($0.78) | ($0.69) | | $0.11 million | View | N/A | |
| 8/13/2014 | | ($0.89) | ($0.77) | $0.56 million | $0.13 million | View | N/A | |
| 5/12/2014 | | ($0.78) | ($0.87) | $1.32 million | $0.45 million | View | N/A | |
| 3/10/2014 | Q4 13 | ($1.07) | ($0.68) | $1.07 million | $1.93 million | View | N/A | |
| 11/12/2013 | Q3 | ($0.66) | ($1.34) | $1.07 million | $1.12 million | View | Listen | |
| 9/6/2013 | Q213 | | ($5.21) | $0.22 million | $0.59 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Onconova Therapeutics (NASDAQ:ONTX)| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q2 2017 | 1 | ($0.72) | ($0.72) | ($0.72) |
| Q3 2017 | 1 | ($0.73) | ($0.73) | ($0.73) |
| Q4 2017 | 1 | ($0.74) | ($0.74) | ($0.74) |
(Data provided by Zacks Investment Research)
Dividend History for Onconova Therapeutics (NASDAQ:ONTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Onconova Therapeutics (NASDAQ:ONTX)Insider Ownership Percentage: 27.30%
Institutional Ownership Percentage: 26.83%
Insider Trades by Quarter for Onconova Therapeutics (NASDAQ:ONTX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 4/26/2017 | E Premkumar Reddy | Director | Buy | 119,048 | $2.10 | $250,000.80 | |
| 4/26/2017 | Mark Patrick Guerin | CFO | Buy | 1,429 | $2.10 | $3,000.90 | |
| 4/26/2017 | Ramesh Kumar | Insider | Buy | 23,810 | $2.10 | $50,001.00 | |
| 2/21/2014 | & Jane Hoffman 2013 De Michael | major shareholder | Buy | 143,480 | $8.47 | $1,215,275.60 | |
| 2/10/2014 | Ramesh Kumar | CEO | Sell | 33,543 | $15.07 | $505,493.01 | |
| 2/3/2014 | Ramesh Kumar | CEO | Sell | 60,000 | $15.05 | $903,000.00 | |
| 1/27/2014 | Michael Hoffman | Director | Buy | 57,295 | $11.92 | $682,956.40 | |
| 11/22/2013 | Michael Hoffman | Director | Buy | 5,000 | $14.39 | $71,950.00 | |
| 11/18/2013 | E Premkumar Reddy | Director | Buy | 5,000 | $12.10 | $60,500.00 | |
| 11/15/2013 | & Jane Hoffman 2013 De Michael | major shareholder | Buy | 19,700 | $11.99 | $236,203.00 | |
| 11/15/2013 | Henry Bienen | Director | Buy | 1,400 | $12.17 | $17,038.00 | |
| 11/15/2013 | Ramesh Kumar | CEO | Buy | 1,100 | $12.02 | $13,222.00 | |
| 7/30/2013 | & Jane Hoffman 2013 De Michael | Major Shareholder | Buy | 1,000,000 | $15.00 | $15,000,000.00 | |
| 7/30/2013 | Ramesh Kumar | CEO | Buy | 6,667 | $15.00 | $100,005.00 | |
| 7/30/2013 | Thomas J Mckearn | Insider | Buy | 3,333 | $15.00 | $49,995.00 | |
| 7/30/2013 | Viren Mehta | Director | Buy | 16,667 | $15.00 | $250,005.00 | |
| 7/25/2013 | E Premkumar Reddy | Director | Buy | 1,000 | $22.72 | $22,720.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Onconova Therapeutics (NASDAQ:ONTX)
Latest Headlines for Onconova Therapeutics (NASDAQ:ONTX)
| Source: |
|
Loading headlines, please wait.
Onconova Therapeutics (ONTX) Chart for Saturday, October, 21, 2017
